The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.

Kamada begins patient enrolment in an investigator-initiated clinical trial of Cytogam to prevent cytomegalovirus in kidney transplantation: Rehovot, Israel Thursday, November 6, ...

Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of ...

Declining immune responsiveness with age may be driven by changes in immune cells — not by inflammation, as previously ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

Kamada (KMDA) announced that the first patient was enrolled into an investigator-initiated post-marketing clinical trial of CYTOGAM, CMV-IGIV, to ...

Doctors in Belgium met with a real head-scratcher when an 83-year-old married man came in with a rare form of secondary ...

People who caught the flu were up to six times more likely to have a heart attack in the month after the infection.

The latest announcement is out from Kamada ( (IL:KMDA) ).

and is expected to have activity against CMV, HHV-6, and HHV-8 as well. The Company has also developed an anti-HIV drug ...

HealthDay News — Viral infections, including HIV and influenza, are associated with an increased risk of cardiovascular disease, including coronary heart disease (CHD) and stroke, according to a study ...